Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-azacitidine + Vorinostat in Relapsed or Refractory DLBCL
NCT01120834Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2010
- Primary completion
- Apr 2013
- Countries
- 1
- Sponsor
- Weill Cornell Medicine
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and vorinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Weill Cornell Medicine. Primary endpoint: Overall Response Rate. Started Sep 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
all subjects
Patients receiving Azacitidine + Vorinostat at assigned dose level
03
Who it enrols
Patients with relapsed/refractory DLBCL who have progressed after or are ineligible for autologous stem cell transplant. Must have measurable disease and adequate organ function.
04
Endpoints
Primary
Overall Response Rate
Beyond the preview
Go deeper on NCT01120834.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120834.